C M P Medica LLC * The Oncology Group

SHERPA: Unknown

People

  1. Hudis
    Hudis
  2. Saltz
    Saltz
  3. Seidman
    Seidman
  4. O'Reilly
    O'Reilly
  5. Ilson
    Ilson
  6. Kelsen
    Kelsen
  7. Kris
    Kris
  8. Bosl
    Bosl
  9. Breitbart
    Breitbart
  10. Sonoda
    Sonoda

Groups

  1. Department of Medicine (229)
  2. Solid Tumor Oncology Division (144)
  3. Survivorship Research (81)
  4. Division of Subspecialty Medicine (63)
  5. Surgery (62)
  6. Integrative Medicine (52)
  7. Breast Medicine Service (49)
  8. Gastrointestinal Oncology Service (39)
  9. Population Sciences Research Program (37)
  10. Hematologic Malignancies, Division of (31)
Search Within
Formats
  1. Journal Article (426)
  2. Editorial (12)
  3. Review (11)
  4. Conference Paper (10)
  5. Miscellaneous (8)
  6. Correspondence (4)
Groups
  1. Department of Medicine (229)
  2. Solid Tumor Oncology Division (144)
  3. Survivorship Research (81)
  4. Division of Subspecialty Medicine (63)
  5. Surgery (62)
  6. Integrative Medicine (52)

More Groups

People
  1. Barrie Cassileth (46)
  2. Bruce Minsky (17)
  3. Andrew Seidman (14)
  4. Clifford Hudis (14)
  5. Leonard Saltz (14)
  6. Eileen O'Reilly (10)

More People

Years
  1. 2025 (8)
  2. 2024 (10)
  3. 2023 (1)
  4. 2022 (2)
  5. 2021 (7)
  6. 2020 (6)

More Years

Publications
  1. Oncology (Norwalk) (471)

Results (471)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Current treatment of peripheral T-cell lymphoma
    Review

    Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Lewis, N.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.
    Oncology (Norwalk) (2022)

    Fulltext@MSK | Save
  • Relapsed/refractory HER2+ metastatic breast cancer
    Editorial

    Brufsky, A. M.; Gadi, V. K.; Hurvitz, S. A.; Iyengar, N. M.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • Real-world assessment of patient care and practice efficiency with the introduction of subcutaneous rituximab
    Journal Article

    Drill, E.; Qiu, A.; Shapouri, S.; Tu My, T.; Ravelo, A.; Schade, J.; Dawson, K.; Matasar, M.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • Updates in therapies of relapsed and refractory follicular lymphoma [Interview]
    Miscellaneous

    Batlevi, C. L.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • Updates in HER2-positive metastatic breast cancer
    Editorial

    Gadi, V. K.; Iyengar, N.; Isaacs, C.; Kaklamani, V.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • Management of chemotherapy-ineligible acute myeloid leukemia: Beyond hypomethylating agent monotherapy
    Editorial

    Stein, E. M.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • Transplant-associated thrombotic microangiopathy (TA-TMA): Integrating new data to improve patient outcomes
    Review

    Giralt, S. A.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • Patient-reported outcomes of pain and related symptoms in integrative oncology practice and clinical research: Evidence and recommendations
    Review

    Zhi, W. I.; Gentile, D.; Diller, M.; Kinney, A.; Bao, T.; Master, V.; Wang, X. S.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • The path to improving breast cancer outcomes: Targeting the androgen receptor pathway in triple-negative breast cancer [Interview]
    Miscellaneous

    Traina, T. A.
    Oncology (Norwalk) (2020)

    Fulltext@MSK | Save
  • FDA approves nivolumab plus ipilimumab for previously untreated unresectable malignant pleural mesothelioma - Comment
    Editorial

    Zauderer, M. G.
    Oncology (Norwalk) (2020)

    Fulltext@MSK | Save

    • C M P Medica LLC * The Oncology Group – authorized name for: